Mei‐Kuang Chen
- Oncology top 5%
- Molecular Biology
- Immunology top 10%
- Pulmonary and Respiratory Medicine
- Cancer Research
- Co-authors
- Mien‐Chie HungJennifer L. HsuJung-Mao HsuYi DuHirohito YamaguchiYongkun WeiGabriel N. HortobágyiJennifer K. Litton
- Topics
- PARP inhibition in cancer therapy (9 papers)Cancer-related Molecular Pathways (6 papers)DNA Repair Mechanisms (4 papers)
- Partner nations
- United StatesTaiwanChina
In The Last Decade
Mei‐Kuang Chen
24 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 912
- Molecular Biology 527
- Immunology 348
- Pulmonary and Respiratory Medicine 191
- Cancer Research 131
Countries citing papers authored by Mei‐Kuang Chen
This map shows the geographic impact of Mei‐Kuang Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Kuang Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Kuang Chen more than expected).
Fields of papers citing papers by Mei‐Kuang Chen
This network shows the impact of papers produced by Mei‐Kuang Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Kuang Chen. The network helps show where Mei‐Kuang Chen may publish in the future.
Co-authorship network of co-authors of Mei‐Kuang Chen
This figure shows the co-authorship network connecting the top 25 collaborators of Mei‐Kuang Chen. A scholar is included among the top collaborators of Mei‐Kuang Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei‐Kuang Chen. Mei‐Kuang Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 4 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer. | 1 |
| 6 | PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation. | 13 |
| 7 | Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. | 15 |
| 8 | 1 | |
| 9 | 18 | |
| 10 | Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. | 36 |
| 11 | Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. | 21 |
| 12 | 11 | |
| 13 | 18 | |
| 14 | 1 | |
| 15 | Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. | 29 |
| 16 | 59 | |
| 17 | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppressionbreakdown → | 768 |
| 18 | A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. | 4 |
| 19 | 64 | |
| 20 | 10 |
About Mei‐Kuang Chen
Mei‐Kuang Chen is a scholar working on Oncology, Orthodontics and Immunology and Allergy, having authored 24 papers that have together received 1.2k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (9 papers), Cancer-related Molecular Pathways (6 papers) and DNA Repair Mechanisms (4 papers). The work is most often cited by research in Oncology (912 citations), Immunology (348 citations) and Reproductive Medicine (105 citations). Mei‐Kuang Chen has collaborated with scholars based in United States, Taiwan and China. Frequent co-authors include Mien‐Chie Hung, Jennifer L. Hsu, Jung-Mao Hsu, Yi Du, Hirohito Yamaguchi, Yongkun Wei, Gabriel N. Hortobágyi, Jennifer K. Litton, Wen-Hsuan Yu and Seung-Oe Lim. Their work appears in journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.